Day 2 ASCO 21 unveiled several results from several trials investigating novel approaches to treat several types of cancers. DelveInsight has documented key abstracts from the ocean that are bound to impact the overall Hematological Cancer market.
Abstract #7518: Epcoritamab demonstrates significant single-agent activity and absence of serious neurotoxicity in phase I/II dose-escalation study
Genmab and AbbVie presented the promising phase I/II clinical data of Epcoritamab in patients with heavily pretreated relapsed/refractory B-cell non-Hodgkin lymphoma. Epcoritamab is an investigational IgG1-bispecific antibody designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab showed an overall response rate (ORR) of 68.2% and complete response (CR) of 45.5% in patients with R/R DLBCL receiving epcoritamab dose ≥12 mg. In these patients, the median duration of response (DOR) was not reached and median progression free survival (PFS) was 9.1 months. In patients with R/R DLBCL receiving epcoritamab dose 48-60 mg, ORR was 91% and CR was 55%, however, median DOR and PFS were not reached. In patients with R/R FL receiving epcoritamab dose 12-48 mg, ORR was 80% and CR was 60%.
The results were promising as there were no reported serious neurotoxicity or CRS events. Based on these results several trials evaluating epicoritamab are ongoing, including phase III trial in R/R DLBCL patients and phase I/II trials in B-cell NHL patients.
